Focal Onset Seizures
Conditions
Brief summary
Proportion of subjects experiencing ≥50% reduction in monthly (28 days) focal seizure frequency from baseline through the DBP for XEN1101 versus placebo
Detailed description
MPC in monthly (28 days) focal seizure frequency from baseline through the DBP for XEN1101 versus placebo, Proportion of subjects experiencing ≥50% reduction in weekly (7 days) focal seizure frequency from baseline to Week 1., Proportion of subjects experiencing “at least much improved” (including “much” and “very much improved”) in PGI-C at Week 12.
Interventions
Sponsors
Xenon Pharmaceuticals Inc.
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of subjects experiencing ≥50% reduction in monthly (28 days) focal seizure frequency from baseline through the DBP for XEN1101 versus placebo | — |
Secondary
| Measure | Time frame |
|---|---|
| MPC in monthly (28 days) focal seizure frequency from baseline through the DBP for XEN1101 versus placebo, Proportion of subjects experiencing ≥50% reduction in weekly (7 days) focal seizure frequency from baseline to Week 1., Proportion of subjects experiencing “at least much improved” (including “much” and “very much improved”) in PGI-C at Week 12. | — |
Countries
Bulgaria, Czechia, Germany, Ireland, Italy, Latvia, Poland, Portugal, Spain
Outcome results
None listed